Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Hansa Biopharma AB's share price for the quarter that ended in Mar. 2026 was kr31.88. Hansa Biopharma AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 99.7 Mil. Therefore, Hansa Biopharma AB's market cap for the quarter that ended in Mar. 2026 was kr3,179.5 Mil.
Hansa Biopharma AB's quarterly market cap
increased
from Sep. 2025 (kr3,264.4 Mil) to Dec. 2025 (kr3,426.9 Mil) but then
declined
from Dec. 2025 (kr3,426.9 Mil) to Mar. 2026 (kr3,179.5 Mil).
Hansa Biopharma AB's annual market cap
increased
from Dec. 2023 (kr1,380.0 Mil) to Dec. 2024 (kr2,571.9 Mil) and
increased
from Dec. 2024 (kr2,571.9 Mil) to Dec. 2025 (kr3,426.9 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Hansa Biopharma AB's Enterprise Value for Today is kr3,996.4 Mil.
Hansa Biopharma AB (OSTO:HNSA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Hansa Biopharma AB Market Cap Related Terms
Hansa Biopharma AB Market Cap Historical Data
* Premium members only.
The historical data trend for Hansa Biopharma AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:HNSA vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Hansa Biopharma AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansa Biopharma AB Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Hansa Biopharma AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Hansa Biopharma AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansa Biopharma AB (OSTO:HNSA) has a Market Cap of kr3,530.6 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Hansa Biopharma AB and its competitors. According to the industry distribution chart, Hansa Biopharma AB ranks #479 out of 1427 companies in the Biotechnology industry, placing it in the top 33.6%.
Is Hansa Biopharma AB's Market Cap too high?
Hansa Biopharma AB's current Market Cap is kr3,530.6 Mil. Based on the distribution chart, Hansa Biopharma AB ranks #479 out of 1427 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Hansa Biopharma AB has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hansa Biopharma AB ranks #479 out of 1427 companies for Market Cap. This puts Hansa Biopharma AB in the upper half of its industry. The industry median Market Cap is 119.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.57, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Hansa Biopharma AB and its competitors. For the Biotechnology industry, the median Market Cap is 119.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansa Biopharma AB's current Market Cap is kr3,530.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (OSTO:HNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is kr24.52, compared to a current price of kr35.40 — trading 44.4% above its estimated fair value. The current Market Cap is kr3,530.6 Mil. Hansa Biopharma AB's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Hansa Biopharma AB (OSTO:HNSA), the current Market Cap is kr3,530.6 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansa Biopharma AB (OSTO:HNSA) Overvalued in 2026?
Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued.
The current stock price of kr35.40 is trading 44.4% above its estimated GF Value™ of kr24.52.
GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.
Key valuation signals for OSTO:HNSA:
Market Cap: kr3,530.6 Mil
GF Value™: kr24.52 vs. price of kr35.40 (44.4% above fair value)
No single metric tells the full story. See the OSTO:HNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
49GF Score
Get the complete analysis for OSTO:HNSA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:HNSA has been successfully added to your 
